DuBois G C, Appella E, Law L W
Int J Cancer. 1984 Oct 15;34(4):561-6. doi: 10.1002/ijc.2910340420.
A tumor rejection antigen (TATA), obtained from the cytosol of a BALB/c mKSA sarcoma induced by SV40 virus, has been partially purified. This partially purified antigen is strikingly immunogenic against mKSA, providing more than 90% inhibition of growth at levels of 10-30 micrograms. This antigen preparation does not protect against challenge with another SV40-induced BALB/c sarcoma VLM which, however, shares a group-specific TATA with mKSA. The antigen also does not immunize against challenge with the methylcholanthrene-induced sarcomas of BALB/c mice, Meth A, CI-4, CII-7 and CII-10, each of which has its own unique TATA. Binding assays, using ELISA, failed to detect any SV40 antigen in the antigen preparation despite the fact that the large T antigen of SV40 (or fragments of it) constitutes the immunodominant TATA of mKSA.
从由SV40病毒诱导的BALB/c mKSA肉瘤的胞质溶胶中获得了一种肿瘤排斥抗原(TATA),并已进行了部分纯化。这种部分纯化的抗原对mKSA具有显著的免疫原性,在10 - 30微克的水平下可提供超过90%的生长抑制。这种抗原制剂不能保护小鼠免受另一种由SV40诱导的BALB/c肉瘤VLM的攻击,然而,VLM与mKSA共享一种组特异性TATA。该抗原也不能使小鼠对甲基胆蒽诱导的BALB/c小鼠肉瘤Meth A、CI - 4、CII - 7和CII - 10产生免疫,每种肉瘤都有其自身独特的TATA。尽管SV40的大T抗原(或其片段)构成了mKSA的免疫显性TATA,但使用酶联免疫吸附测定(ELISA)的结合试验未能在抗原制剂中检测到任何SV40抗原。